We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Mereo BioPharma

Phase II starts with backing from patient support group

Lighthouse | 05 November 2018


Navigating the opportunity in depression

Update | 11 October 2018


Major milestone achieved, as first patient is treated with a CARMA product

Lighthouse | 10 October 2018


New data support potential in NSCLC

Update | 09 October 2018


Progress in all areas, and a longer cash runway

Lighthouse | 04 October 2018


Putting more flesh on the bones

Update | 01 October 2018

Mereo BioPharma

Raring to go in rare diseases

Initiation | 24 September 2018


Core business continues to deliver, as CARMA enters the clinic

Lighthouse | 24 September 2018


E-FIT stroke trial results disappoint

Update | 04 September 2018

Tissue Regenix

Executing the plan

Update | 03 September 2018
1 2 3 4 5 6 7 8 9 10 11 12 13 14
136 results found.